Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset.
Sai Priya Anand,Jérémie Prévost,Manon Nayrac,Guillaume Beaudoin-Bussières,Mehdi Benlarbi,Romain Gasser,Nathalie Brassard,Annemarie Laumaea,Shang Yu Gong,Catherine Bourassa,Elsa Brunet-Ratnasingham,Halima Medjahed,Gabrielle Gendron-Lepage,Guillaume Goyette,Laurie Gokool,Chantal Morrisseau,Philippe Bégin,Valérie Martel-Laferrière,Cécile Tremblay,Jonathan Richard,Renée Bazin,Ralf Duerr,Daniel Kaufmann,Andrés Finzi,Andrés Finzi +24 more
- Vol. 2, Iss: 6, pp 100290-100290
Reads0
Chats0
TLDR
In this article, the presence of SARS-CoV-2-specific memory B cells in convalescent individuals was evaluated using a longitudinal assessment of humoral immune responses.Abstract:
With the recent approval of highly effective COVID-19 vaccines, functional and lasting immunity to SARS-CoV-2 is currently under investigation as antibody levels in plasma were shown to decline during convalescence. Since the absence of antibodies does not equate to absence of immune memory, we evaluate the presence of SARS-CoV-2-specific memory B cells in convalescent individuals. Here we report a longitudinal assessment of humoral immune responses on 32 donors up to 8 months post-symptom onset. Our observations indicate that anti-Spike and anti-RBD IgM in plasma decay rapidly, whereas the reduction of IgG is less prominent. Neutralizing activity also declines rapidly when compared to Fc-effector functions. Concomitantly, the frequencies of RBD-specific IgM+ B cells wane significantly when compared to RBD-specific IgG+ B cells which remain stable. Our results add to the current understanding of immune memory following SARS-CoV-2 infection, which is critical for the prevention of secondary infections and vaccine efficacy.read more
Citations
More filters
Journal ArticleDOI
Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant.
Venkata Viswanadh Edara,Carson Norwood,Katharine Floyd,Katharine Floyd,Lilin Lai,Lilin Lai,Meredith E. Davis-Gardner,Meredith E. Davis-Gardner,William H. Hudson,Grace Mantus,Lindsay E. Nyhoff,Max W. Adelman,Rebecca Fineman,Shivan N. Patel,Rebecca Byram,Dumingu Nipuni Gomes,Garett Michael,Hayatu Abdullahi,Nour Beydoun,Bernadine Panganiban,Nina N. McNair,Kieffer Hellmeister,Jamila Pitts,Joy Winters,Jennifer Kleinhenz,Jacob Usher,James B O'Keefe,Anne Piantadosi,Jesse J. Waggoner,Ahmed Babiker,David S. Stephens,Evan J. Anderson,Srilatha Edupuganti,Nadine Rouphael,Rafi Ahmed,Jens Wrammert,Mehul S. Suthar +36 more
TL;DR: Despite reduced antibody titers against the B.1.351 variant, sera from infected and vaccinated individuals containing polyclonal antibodies to the spike protein could still neutralize SARS-CoV-2 B. 1.1, suggesting that protective humoral immunity may be retained against this variant.
Journal ArticleDOI
Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial.
Philippe Bégin,Jeannie Callum,Erin Jamula,Richard J. Cook,Nancy M. Heddle,Nancy M. Heddle,Alan Tinmouth,Alan Tinmouth,Alan Tinmouth,Michelle P. Zeller,Michelle P. Zeller,Guillaume Beaudoin-Bussières,Luiz Amorim,Renée Bazin,Kent Cadogan Loftsgard,Richard Carl,Michaël Chassé,Melissa M. Cushing,Nick Daneman,Dana V. Devine,Dana V. Devine,Jeannot Dumaresq,Dean Fergusson,Dean Fergusson,Dean Fergusson,Caroline Gabe,Marshall J. Glesby,Na Li,Na Li,Yang Liu,Allison McGeer,Nancy Robitaille,Nancy Robitaille,Bruce S. Sachais,Bruce S. Sachais,Damon C. Scales,Damon C. Scales,Lisa Schwartz,Nadine Shehata,Nadine Shehata,Nadine Shehata,Alexis F. Turgeon,Heidi Wood,Ryan Zarychanski,Andrés Finzi,Donald M. Arnold +45 more
TL;DR: In this paper, the authors conducted an open-label, randomized controlled trial of convalescent plasma for adults with COVID-19 receiving oxygen within 12 d of respiratory symptom onset ( NCT04348656 ).
Journal ArticleDOI
A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses.
Alexandra Tauzin,Manon Nayrac,Mehdi Benlarbi,Shang Yu Gong,Romain Gasser,Guillaume Beaudoin-Bussières,Nathalie Brassard,Annemarie Laumaea,Dani Vézina,Jérémie Prévost,Sai Priya Anand,Catherine Bourassa,Gabrielle Gendron-Lepage,Halima Medjahed,Guillaume Goyette,Julia Niessl,Olivier Tastet,Laurie Gokool,Chantal Morrisseau,Pascale Arlotto,Leonidas Stamatatos,Leonidas Stamatatos,Andrew T. McGuire,Catherine Larochelle,Pradeep D. Uchil,Maolin Lu,Walther Mothes,Gaston De Serres,Sandrine Moreira,Michel Roger,Jonathan Richard,Valérie Martel-Laferrière,Ralf Duerr,Cécile Tremblay,Daniel Kaufmann,Andrés Finzi,Andrés Finzi +36 more
TL;DR: In this article, a single dose of the BNT162b2 mRNA vaccine for SARS-CoV-2 was found to be up to 90% effective starting 14 days post-administration.
Journal ArticleDOI
Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
Floriane Gallais,Pierre Gantner,Timothée Bruel,Timothée Bruel,Aurélie Velay,Delphine Planas,Delphine Planas,Marie-Josée Wendling,Sophie Bayer,Morgane Solis,Elodie Laugel,Nathalie Reix,Anne Schneider,Ludovic Glady,Baptiste Panaget,Nicolas Collongues,Marialuisa Partisani,Jean-Marc Lessinger,Arnaud Fontanet,Arnaud Fontanet,David Rey,Yves Hansmann,Laurence Kling-Pillitteri,Olivier Schwartz,Olivier Schwartz,Jérôme De Seze,Nicolas Meyer,María González,Catherine Schmidt-Mutter,Samira Fafi-Kremer +29 more
TL;DR: In this article, a prospective, monocentric, longitudinal, cohort clinical study was conducted to assess the kinetics of SARS-CoV-2 antibodies and the incidence of reinfection.
Journal ArticleDOI
Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy.
Irfan Ullah,Jérémie Prévost,Mark S. Ladinsky,Helen Stone,Maolin Lu,Sai Priya Anand,Guillaume Beaudoin-Bussières,Kelly Symmes,Mehdi Benlarbi,Shilei Ding,Romain Gasser,Corby Fink,Yaozong Chen,Alexandra Tauzin,Guillaume Goyette,Catherine Bourassa,Halima Medjahed,Matthias Mack,Kunho Chung,Craig B. Wilen,Gregory A. Dekaban,Jimmy D. Dikeakos,Emily A. Bruce,Daniel Kaufmann,Leonidas Stamatatos,Andrew T. McGuire,Jonathan Richard,Marzena Pazgier,Pamela J. Bjorkman,Walther Mothes,Andrés Finzi,Andrés Finzi,Priti Kumar,Pradeep D. Uchil +33 more
TL;DR: In this paper, the authors applied live bioluminescence imaging (BLI) to monitor the real-time effects of neutralizing antibodies (NAbs) treatment during prophylaxis and therapy of K18-hACE2 mice intranasally infected with SARS-CoV-2-nanoluciferase.
References
More filters
Journal Article
R: A language and environment for statistical computing.
TL;DR: Copyright (©) 1999–2012 R Foundation for Statistical Computing; permission is granted to make and distribute verbatim copies of this manual provided the copyright notice and permission notice are preserved on all copies.
Journal ArticleDOI
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann,Hannah Kleine-Weber,Simon Schroeder,Nadine Krüger,Tanja Herrler,Sandra Erichsen,Tobias S. Schiergens,Georg Herrler,Nai Huei Wu,Andreas Nitsche,Marcel A. Müller,Christian Drosten,Christian Drosten,Stefan Pöhlmann +13 more
TL;DR: It is demonstrated that SARS-CoV-2 uses the SARS -CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming, and it is shown that the sera from convalescent SARS patients cross-neutralized Sars-2-S-driven entry.
Journal ArticleDOI
Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.
Alexandra C. Walls,Young-Jun Park,M. Alejandra Tortorici,M. Alejandra Tortorici,Abigail Wall,Andrew T. McGuire,Andrew T. McGuire,David Veesler +7 more
TL;DR: It is demonstrating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination, and it is shown that SARS-CoV-2 S uses ACE2 to enter cells and that the receptor-binding domains of Sars- coV- 2 S and SARS S bind with similar affinities to human ACE2, correlating with the efficient spread of SATS among humans.
Journal ArticleDOI
Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals.
Alba Grifoni,Daniela Weiskopf,Sydney I. Ramirez,Sydney I. Ramirez,Jose Mateus,Jennifer M. Dan,Jennifer M. Dan,Carolyn Rydyznski Moderbacher,Stephen A. Rawlings,Aaron Sutherland,Lakshmanane Premkumar,Ramesh Jadi,Daniel Marrama,Aravinda M. de Silva,April Frazier,Aaron F. Carlin,Jason A. Greenbaum,Bjoern Peters,Bjoern Peters,Florian Krammer,Davey M. Smith,Shane Crotty,Shane Crotty,Alessandro Sette,Alessandro Sette +24 more
TL;DR: Using HLA class I and II predicted peptide ‘megapools’, circulating SARS-CoV-2−specific CD8+ and CD4+ T cells were identified in ∼70% and 100% of COVID-19 convalescent patients, respectively, suggesting cross-reactive T cell recognition between circulating ‘common cold’ coronaviruses and SARS.
Journal ArticleDOI
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Jennifer M. Dan,Jennifer M. Dan,Jose Mateus,Yu Kato,Kathryn M. Hastie,Esther Dawen Yu,Caterina E. Faliti,Alba Grifoni,Sydney I. Ramirez,Sydney I. Ramirez,Sonya Haupt,April Frazier,Catherine Nakao,Vamseedhar Rayaprolu,Stephen A. Rawlings,Bjoern Peters,Bjoern Peters,Florian Krammer,Viviana Simon,Erica Ollmann Saphire,Erica Ollmann Saphire,Davey M. Smith,Daniela Weiskopf,Alessandro Sette,Alessandro Sette,Shane Crotty,Shane Crotty +26 more
TL;DR: This article analyzed multiple compartments of circulating immune memory to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 254 samples from 188 COVID-19 cases, including 43 samples at ≥ 6 months after infection.
Related Papers (5)
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.
Jennifer M. Dan,Jennifer M. Dan,Jose Mateus,Yu Kato,Kathryn M. Hastie,Esther Dawen Yu,Caterina E. Faliti,Alba Grifoni,Sydney I. Ramirez,Sydney I. Ramirez,Sonya Haupt,April Frazier,Catherine Nakao,Vamseedhar Rayaprolu,Stephen A. Rawlings,Bjoern Peters,Bjoern Peters,Florian Krammer,Viviana Simon,Erica Ollmann Saphire,Erica Ollmann Saphire,Davey M. Smith,Daniela Weiskopf,Alessandro Sette,Alessandro Sette,Shane Crotty,Shane Crotty +26 more
Evolution of antibody immunity to SARS-CoV-2.
Christian Gaebler,Zijun Wang,Julio C. C. Lorenzi,Frauke Muecksch,Shlomo Finkin,Minami Tokuyama,Alice Cho,Mila Jankovic,Dennis Schaefer-Babajew,Thiago Y. Oliveira,Melissa Cipolla,Charlotte Viant,Christopher O. Barnes,Yaron Bram,Gaëlle Breton,Thomas Hagglof,Pilar Mendoza,Arlene Hurley,Martina Turroja,Kristie Gordon,Katrina G. Millard,Victor A. Ramos,Fabian Schmidt,Yiska Weisblum,Divya Jha,Michael Tankelevich,Gustavo Martinez-Delgado,Jim Yee,Roshni Patel,Juan Dizon,Cecille Unson-O'Brien,Irina Shimeliovich,Davide F. Robbiani,Zhen Zhao,Anna Gazumyan,Robert E. Schwartz,Theodora Hatziioannou,Pamela J. Bjorkman,Saurabh Mehandru,Paul D. Bieniasz,Paul D. Bieniasz,Marina Caskey,Michel C. Nussenzweig,Michel C. Nussenzweig +43 more
Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans.
Jeffrey Seow,Carl Graham,Blair Merrick,Sam Acors,Suzanne Pickering,Kathryn J. A. Steel,Oliver Hemmings,Aoife M O'Byrne,Neophytos Kouphou,Rui Pedro Galão,Gilberto Betancor,Harry Wilson,Adrian W. Signell,Helena Winstone,Claire Kerridge,Isabella Huettner,Jose M. Jimenez-Guardeño,Maria Jose Lista,Nigel J. Temperton,Luke B Snell,Karen Bisnauthsing,Amelia E. B. Moore,Adrian Green,Lauren Martinez,Brielle Stokes,Johanna Honey,Alba Izquierdo-Barras,Gill Arbane,Amita Patel,Mark Kia Ik Tan,Lorcan O’Connell,Geraldine O’Hara,Eithne MacMahon,Sam Douthwaite,Gaia Nebbia,Rahul Batra,Rocio T. Martinez-Nunez,Manu Shankar-Hari,Manu Shankar-Hari,Jonathan D. Edgeworth,Jonathan D. Edgeworth,Stuart J. D. Neil,Michael H. Malim,Katie J. Doores +43 more